Steven Finkelstein, MD, FACRO, Florida Cancer Affiliates
Articles
Between the Lines Podcast: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer
October 19th 2021Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.
Prostate Cancer: Clinical Implications From the EMPIRE-1 Trial
Drs Brian Helfand and Steven Finkelstein share key takeaways and clinical pearls from the phase 2/3 EMPIRE-1 trial for prostate cancer.
Phase 2/3 EMPIRE-1 Trial in Prostate Cancer
Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, review results from the phase 2/3 EMPIRE-1 trial examining the use of ¹⁸F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy for prostate cancer.
